Linked Life Data

7298796

Source:http://linkedlifedata.com/resource/pubmed/id/7298796

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1982-1-28
pubmed:keyword
http://linkedlifedata.com/resource/pubmed/keyword/Alcohol Drinking, http://linkedlifedata.com/resource/pubmed/keyword/Biology, http://linkedlifedata.com/resource/pubmed/keyword/Contraception, http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents, Female, http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents, Progestin, http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Methods--side effects, http://linkedlifedata.com/resource/pubmed/keyword/DIMETHISTERONE, http://linkedlifedata.com/resource/pubmed/keyword/ETHINYL ESTRADIOL, http://linkedlifedata.com/resource/pubmed/keyword/ETHYNODIOL DIACETATE, http://linkedlifedata.com/resource/pubmed/keyword/Educational Status, http://linkedlifedata.com/resource/pubmed/keyword/Endocrine System, http://linkedlifedata.com/resource/pubmed/keyword/Estrogens--analysis, http://linkedlifedata.com/resource/pubmed/keyword/Ethnic Groups, http://linkedlifedata.com/resource/pubmed/keyword/Family Planning, http://linkedlifedata.com/resource/pubmed/keyword/Hormones, http://linkedlifedata.com/resource/pubmed/keyword/LIPIDS, http://linkedlifedata.com/resource/pubmed/keyword/Lipid Metabolic Effects--analysis, http://linkedlifedata.com/resource/pubmed/keyword/Menstrual Cycle, http://linkedlifedata.com/resource/pubmed/keyword/Mestranol, http://linkedlifedata.com/resource/pubmed/keyword/Norethindrone, http://linkedlifedata.com/resource/pubmed/keyword/Norethindrone Acetate, http://linkedlifedata.com/resource/pubmed/keyword/OCCUPATIONS, http://linkedlifedata.com/resource/pubmed/keyword/Oral Contraceptives, Combined, http://linkedlifedata.com/resource/pubmed/keyword/Oral Contraceptives, Phasic, http://linkedlifedata.com/resource/pubmed/keyword/Oral Contraceptives--side effects, http://linkedlifedata.com/resource/pubmed/keyword/Physiology, http://linkedlifedata.com/resource/pubmed/keyword/Progestational Hormones, http://linkedlifedata.com/resource/pubmed/keyword/Progesterone--analysis, http://linkedlifedata.com/resource/pubmed/keyword/SMOKING
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0021-972X
pubmed:author
pubmed:issnType
Print
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1123-32
pubmed:dateRevised
2006-11-15
pubmed:otherAbstract
PIP: A study of the prevalence of hyperlipidemia has been conducted among female telephone company employees using oral contraceptives (OCs) or estrogenic hormones. This paper relates hormone formulation and estrogen/progestin potency to striglyceride and cholesterol concentrations in total plasma and lipoprotein fractions and relative lipid composition. Changes in these lipid parameters are of interest because they may predict atherosclerosis risk. Results in 148 hormone users are compared with those in 306 nonhormone users. All data are adjusted for the effects of age, relative body weight, cigarette smoking, and alcohol intake. Triglyceride concentrations in whole plasma, very low density lipoprotein (VLDL), and high density lipoprotein (HDL) are elevated 1.5-2.5 fold with increasing estrogen potency. Low density lipoprotein (LDL) triglyceride concentration is elevated to a similar degree among OC users regardless of estrogen potency, but there is no significant effect of postmenopausal estrogen use on LDL triglyceride concentrations. The LDL cholesterol concentration shows an increasing trend with increasing estrogen potency in a random sample of OC-treated women, but is slightly lower than control in postmenopausal women treated with estrogen alone. The HDL cholesterol concentration in plasma is highest with hormones having the greatest estrogen potency and lowest with those having the greatest progestin potency. The VLDL cholesterol to triglyceride ratio adjusted for triglyceride concentration is significantly increased with the use of Ovral, a progestin-predominant contraceptive preparation. The LDL cholesterol to triglyceride ratio is reduced with the use of all OCs examined, except for Ovral, where the ratio is above average. The HDL cholesterol to triglyceride ratio is reduced for all combination OCs examined. The use of a sequential OC or postmenopausal estrogens is not associated with a significant alteration in the cholesterol to triglyceride ratio in any lipoprotein fraction. Knowledge of estrogen and progestin potency and kind of progestin are important in predicting the effect of OCs on plasma and lipoprotein lipids. On the basis of observed differences in lipoprotein lipid concentrations and relationships, the potential arteriosclerotic risk from sex hormones may vary among OC formulations.
pubmed:meshHeading
pubmed:year
1981
pubmed:articleTitle
Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't